Debiopharm Takes Up Confirmatory Phase III Trial Of Sanvar
This article was originally published in The Pink Sheet Daily
Executive Summary
The esophageal variceal bleeding treatment received an FDA “approvable” letter in 2004.
You may also be interested in...
GSK’s Rezonic and Debiovision’s Sanvar To Get Advisory Committee Reviews In May
FDA has been digesting both applications for a considerable amount of time.
GSK’s Rezonic and Debiovision’s Sanvar To Get Advisory Committee Reviews In May
FDA has been digesting both applications for a considerable amount of time.
Debiopharm Files Sanvar In France
Swiss-based Debiopharm is seeking European marketing partners for its somatostatin analog Sanvar (vapreotide acetate), the company said July 24